David H. Ilson, MD, PhD, of Memorial Sloan Kettering Cancer Center, discusses the merits of preoperative chemotherapy vs chemoradiotherapy, the role of targeted agents, recent results from genomic profiling, and whether PET scans can guide neoadjuvant treatment.
Manish A. Shah, MD, of Weill Cornell Medicine, discusses phase III study findings on cisplatin plus capecitabine or fluorouracil with or without ramucirumab as first-line therapy in patients with metastatic gastric or gastroesophageal junction adenocarcinoma (Abstract 5).
Khaldoun Almhanna, MD, MPH, of the H. Lee Moffitt Cancer Center, discusses the long-term outcome of a phase III study that explored the significance of extensive intraoperative peritoneal lavage in addition to standard treatment for ≥ T3 resectable gastric cancer (Abstract 1).
Abraham J. Wu, MD, of Memorial Sloan Kettering Cancer Center, discusses his findings that suggest efforts to reduce lung dose, such as shrinking the treatment volumes or using proton therapy, may improve outcomes in esophageal cancer (Abstract 3).
Florian Lordick, MD, of the University Medicine Leipzig, discusses study findings on intraperitoneal immunotherapy with the antibody catumaxomab for patients with peritoneal carcinomatosis from gastric cancer (Abstract 4).
Mark Saunders, MD, PhD, of Christie Hospital, discusses study findings on tumor sidedness and the influence of chemotherapy duration on disease-free survival (Abstract 558).
